[
    {
        "file_name": "HarpoonTherapeuticsInc_20200312_10-K_EX-10.18_12051356_EX-10.18_Development Agreement_Option Agreement.pdf",
        "perturbation": [
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "Within [***] after the Effective Date, the Parties shall establish a joint governance committee (the “Joint Governance Committee” or “JGC”). The JGC shall consist of [***] representatives from each of the Parties, each with the requisite experience and seniority to enable such person to make decisions on behalf of the Parties with respect to the issues falling within the jurisdiction of the JGC. From time to time, each Party may substitute [***] or more of its representatives to the JGC on written notice to the other Party. [***] shall select from its representatives the chairperson for the JGC.",
                "changed_text": "Within [***] after the Effective Date, the Parties shall establish a joint governance committee (the “Joint Governance Committee” or “Oversight Board”). The JGC shall consist of [***] representatives from each of the Parties, each with the requisite experience and seniority to enable such person to make decisions on behalf of the Parties with respect to the issues falling within the jurisdiction of the Oversight Board. From time to time, each Party may substitute [***] or more of its representatives to the Oversight Board on written notice to the other Party. [***] shall select from its representatives the chairperson for the Oversight Board.",
                "explanation": "The change from 'Joint Governance Committee' or 'JGC' to 'Joint Governance Committee' or 'Oversight Board' introduces uncertainty and potential contradiction, as the contract now uses two different terms for what is ostensibly the same entity, without explicitly stating that they are interchangeable. This could lead to confusion regarding the committee's responsibilities and authority.",
                "location": "2.1.1"
            },
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "Each Party shall have the right to subcontract any of its Development activities to a Third Party (a “Third Party Provider”); provided that, solely with respect of Third Party Providers performing services that are critical or material to the Licensed Compound or Licensed Products (such as contract research organizations and contract manufacturing organizations,) Harpoon must (a) [***] (b) except with respect to Third Party Providers [***] and (c) obtain a written undertaking from the Third Party Provider sufficient for Harpoon to comply with the applicable terms and conditions of this Agreement, including the confidentiality provisions of Article 9.",
                "changed_text": "Each Party shall have the right to subcontract any of its Development activities to a Third Party (a “Third Party Provider”); provided that, solely with respect of Third Party Contractors performing services that are critical or material to the Licensed Compound or Licensed Products (such as contract research organizations and contract manufacturing organizations,) Harpoon must (a) [***] (b) except with respect to Third Party Contractors [***] and (c) obtain a written undertaking from the Third Party Contractor sufficient for Harpoon to comply with the applicable terms and conditions of this Agreement, including the confidentiality provisions of Article 9.",
                "explanation": "The term 'Third Party Provider' is changed to 'Third Party Contractor', but these terms are not defined or stated to be interchangeable. This introduces confusion around which entities this section applies to, especially since the definition of 'Third Party Provider' exists.",
                "location": "3.7"
            },
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "Effective on the License Option Exercise Closing Date, as between the Parties, AbbVie shall have the sole right, at its expense, to Manufacture (or have Manufactured) and supply the Licensed Compound and Licensed Products for commercial sale in the Territory by AbbVie and its Affiliates and Sublicensees.",
                "changed_text": "Effective on the License Option Exercise Closing Date, as between the Parties, AbbVie shall have the sole right, at its expense, to Produce (or have Produced) and supply the Licensed Compound and Licensed Products for commercial sale in the Territory by AbbVie and its Affiliates and Sublicensees.",
                "explanation": "The term 'Manufacture' is changed to 'Produce,' yet 'Manufacture' continues to be used elsewhere in the document, and is a term defined in the contract. This creates an internal inconsistency.",
                "location": "4.5.1"
            }
        ]
    }
]